BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2014 10:47:00 AM | Browse: 948 | Download: 1172
Publication Name World Journal of Gastroenterology
Manuscript ID 10905
Country Italy
Received
2014-04-25 09:21
Peer-Review Started
2014-04-25 21:12
To Make the First Decision
2014-05-29 19:19
Return for Revision
2014-06-05 19:39
Revised
2014-06-19 05:38
Second Decision
2014-07-30 10:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-07-30 10:19
Articles in Press
2014-07-30 10:45
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-11-13 19:34
Publish the Manuscript Online
2014-12-02 10:46
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Clinical Trials Study
Article Title Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women
Manuscript Source Unsolicited Manuscript
All Author List Veronica Bernabucci, Alessia Ciancio, Salvatore Petta, Aimilia Karampatou, Laura Turco, Silvia Strona, Rosina Critelli, Paola Todesca, Caterina Cerami, Caterina Sagnelli, Mario Rizzetto, Calogero Cammà and Erica Villa
Funding Agency and Grant Number
Funding Agency Grant Number
Schering-Plough (now Merck)
Corresponding Author Erica Villa, Professor, Division of Gastroenterology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università degli Studi di Modena e Reggio Emilia, via del Pozzo 71, 41124 Modena, Italy. erica.villa@unimore.it
Key Words Hepatitis C virus treatment; Pegylated Interferon; Viral Hepatitis; Menopause; Genotype 1
Core Tip After menopause liver disease in hepatitis C virus-positive women becomes rapidly progressive, severe fibrosis develops, and response to antiviral therapy becomes very low. Re-treatment with standard dual therapy in previous failures of Peginterferon-??+ Ribavirin (PEG-IFN?/RBV) treatments does not achieve more than 5%-10% sustained virological response (SVR). The addition of Boceprevir to PEG-IFN?/RBV in menopausal women with HCV-1 genotype infection, who had previously failed dual antiviral therapy, determined a striking improvement of SVR. More than 45% of women re-treated with triple therapy achieved SVR, with few side effects and good tolerability. Response after 4 wk of Boceprevir was the only independent factor predicting SVR.
Publish Date 2014-12-02 10:46
Citation Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. World J Gastroenterol 2014; 20(44): 16726-16733
URL http://www.wjgnet.com/1007-9327/full/v20/i44/16726.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i44.16726
Full Article (PDF) WJG-20-16726.pdf
Full Article (Word) WJG-20-16726.doc
Manuscript File 10905-Review.docx
Answering Reviewers 10905-Answering Reviewers.pdf
Copyright License Agreement 10905-Copyright assignment.pdf
Institutional Review Board Approval Form or Document Ethics_Committee_20140425005605.pdf
Non-Native Speakers of English Editing Certificate 10905-Language certificate.pdf
Peer-review Report 10905-Peer review.pdf
Scientific Misconduct Check 10905-CorssCheck.jpg
Scientific Editor Work List 10905-Scientific editor work list.pdf